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Understanding Anticoagulation Decisions in Atrial Fibrillation

John Cassel and Zhe Chen, M.D.
Lehigh Valley Health Network, Allentown, Pennsylvania

Background
• Atrial fibrillation (AF) is an abnormal
heart rhythm defined by irregular,
uncoordinated beating of the atria1
• AF disrupts cardiac blood flow, leading
to the formation of thrombi that can then
embolize, occluding cerebral blood flow2
• Untreated AF confers a fivefold
increased risk of ischemic stroke3
• Treatment with anticoagulant medication
reduces stroke risk; but increases
bleeding risk4,5
• Evidence-based guidelines exist to
inform treatment decisions5.
• Only a fraction of eligible patients
receive appropriate treatment in
accordance with guidelines6

Discussion

Results

• Plurality of patients (42.9%) denied
OAC due to bleed or fall risk

• Demographics
– 205 of 526 patients eligible for inclusion
– Mean age of 81 years
– 54% female

– Inconsistent with current guidelines
– Modifiable risk factors
– Targets for physician- and patientdirected educational interventions

• Physicians have legitimate
concerns and are accurately
identifying patients at higher risk of
bleeding
– Increased use of shared decision
making may assist proper
navigation of risks / benefits of
OAC

Table 1: Patient Characteristics - Comorbidities of patient population
CKD: Chronic Kidney Disease, CHF: Congestive Heart Failure, ICH: Intracerebral
hemorrhage, SDH: Subdural hematoma, SAH: Subarachnoid hemorrhage

• Low usage rate of left atrial
appendage occlusion surgery

Problem Statement
The purpose of the present study is to assess, via
review of physician-authored medical documentation,
the reasons for prescriber avoidance of
anticoagulation in patients with histories of both
atrial fibrillation and stroke, and the clinical
characteristics of these patients.

Conclusions

Table 2: Reasons for Withholding OAC Medication.
LAA: Left atrial appendage, Declined: Patient or caregiver declined treatment, Comfort
measures: End-of-life or hospice care, AF due to another medical…: AF due to specific
time-limited or treatable condition

• Both OAC treatment and withholding
carry the potential for catastrophic
outcomes
• The gravity of this decision requires
special attention to patient education
and involvement in the decisionmaking process, including:

Methods
• Retrospective chart review of current
LVHN patients
• Inclusion criteria:
– History of atrial fibrillation
• ICD-10: I48.0 – I48.4, I48.9
• Documented diagnostic
evidence of AF
– History of stroke
• ICD-10: I63.0 – I63.9

– Shared-decision making tools
– Visual aids for patient education
– Usage of composite risk / benefit, “Net
clinical benefit,” measures in both
physician and patient-directed
education

Table 3: Risk Stratification
Compares CHA₂DS₂-VASc and HAS-BLED scores of patients deemed bleed risks, fall risks,
and those who declined treatment with the cohort as a whole.
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